- Bloomberg•23 days ago
Lupin Ltd.’s point man for mergers and acquisitions figures he has about $1 billion to work with as he hunts for targets to hasten the Indian firm’s move from simple generic drugs to more profitable products. ...
- Business Wire•4 months ago
Pharma Major Lupin Limited announced today that its US subsidiary Lupin Pharmaceuticals, Inc. has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration to market a generic version of Cephalon, Inc.’s Nuvigil® Tablets 50 mg, 150 mg, 200 mg and 250 mg.
- Bloomberg•6 months ago
Lupin Ltd., India’s second-biggest drugmaker by market value, expects U.S. approvals for new products from its facility in the coastal state of Goa to begin again in the next two months as it addresses ...
LUPIN.NS : Summary for LUPIN LTD INR2 - Yahoo Finance
Lupin Limited (LUPIN.NS)
NSE - NSE Real Time Price. Currency in INR
Add to watchlist
|Day's Range||1,445.00 - 1,457.00|
|52 Week Range||1,382.60 - 1,750.00|
|PE Ratio (TTM)||22.34|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|